PerkinElmer said today it agreed to acquire BioLegend, a provider of life science antibodies and reagents, for approximately $5.25 billion in cash and stock—the largest acquisition in the buyer’s ...

BioLegend can breathe a bit easier. The San Diego biological research products supplier, which had been cramped for space, opened a new and larger headquarters this week. BioLegend has more than 500 ...

The BioLegend Campus Extension started in 2015 with a four-year master plan to privatize a public street and convert the existing 7.5-acre, four-parcel plot into an eight-acre biotechnology campus.

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science ...

A technology developed at the New York Genome Center that combines protein and messenger RNA expression measurements in cells has been licensed by biotech tools company BioLegend. The San Diego-based ...

The TotalSeq Phenocyte solution supports robust study of cellular heterogeneity and rare cell types in complex samples at a single cell level SAN DIEGO, November 19, 2024--(BUSINESS WIRE)--Scale ...

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, ...

SAN DIEGO, CA--(Marketwire - Mar 7, 2013) - BioLegend in San Diego, CA, a leading provider of antibodies and reagents for biomedical research, has been granted ISO 9001:2008 certification for ...

PerkinElmer Inc. said it is buying BioLegend, which provides life science antibodies and reagents, for $5.25 billion in a combination of cash and stock. PerkinElmer said Monday the transaction is ...

BioLegend founder, President & CEO Gene Lay, and San Diego Mayor Kevin Faulconer, led a group of dignitaries in celebrating the grand opening of Biolegend's new headquarters in San Diego. The company ...

PerkinElmer, Inc. (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 ...